Company Profile
Amneal Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- AMRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
18.07 USD (-2.11%)
Close
Last updated: August 6, 2026
4.04B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AMRX closed down 2.11% at $18.07. No new same-company headline was identified in the current news window.
Company overview
Diversified Affordable Medicines Company
Amneal Pharmaceuticals is a global biopharmaceutical company focused on expanding access to affordable and innovative medicines. Its portfolio includes approximately 300 complex generic, specialty, and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States.
Affordable Medicines and Complex Generics
The Affordable Medicines segment spans retail generics, injectables, and biosimilars. In the second quarter of 2026, this segment grew on strength in complex products, women's health products, and new launches, reinforcing Amneal's role as a scaled provider of lower-cost medicines.
Specialty and AvKARE Segments
Amneal's Specialty segment includes branded treatments in neurology and endocrinology, with growth driven by products such as CREXONT, BREKIYA autoinjector, and UNITHROID. AvKARE distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers, giving the company a separate distribution-focused revenue channel.
Biosimilars as a New Growth Vertical
The pending Kashiv Biosciences transaction is intended to establish biosimilars as a durable growth vertical for Amneal. Combined with debt repricing and guidance increases, the company is positioning itself as a broader affordable-medicines platform with specialty and biosimilar upside.
Future catalysts
Recent news
- 01
Amneal Reports Second Quarter 2026 Financial Results
Source: Amneal Pharmaceuticals
- 02
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
Source: Amneal Pharmaceuticals
- 03
Amneal to Report Second Quarter 2026 Results on July 30, 2026
Source: Amneal Pharmaceuticals
- 04
Amneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector
Source: Amneal Pharmaceuticals
- 05
Amneal’s New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program
Source: Amneal Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
Amneal Pharmaceuticals (AMRX) most recently closed at 18.07 USD, a -2.11% move versus the previous session.
What is the market cap of Amneal Pharmaceuticals (AMRX)?
Amneal Pharmaceuticals currently has a market capitalization of 4.04B USD on BioPharmSignal.
What does Amneal Pharmaceuticals do?
Diversified Affordable Medicines Company Amneal Pharmaceuticals is a global biopharmaceutical company focused on expanding access to affordable and innovative medicines. Its portfolio includes approximately 300 complex generic, specialty, and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United...
On which exchange is AMRX stock listed?
Amneal Pharmaceuticals (AMRX) is associated with NASDAQ, United States, Biopharma.
What is Diversified?
Diversified Affordable Medicines Company Amneal Pharmaceuticals is a global biopharmaceutical company focused on expanding access to affordable and innovative medicines.
Which conditions is Amneal Pharmaceuticals targeting with Diversified?
Amneal Pharmaceuticals is associated with neurology based on its company overview and current catalyst commentary.
What is Affordable?
Diversified Affordable Medicines Company Amneal Pharmaceuticals is a global biopharmaceutical company focused on expanding access to affordable and innovative medicines.
What is Medicines?
Diversified Affordable Medicines Company Amneal Pharmaceuticals is a global biopharmaceutical company focused on expanding access to affordable and innovative medicines.